Diagnosis and management of migraine in ten steps.

Clinical Decision-Making / methods Consensus Denmark / epidemiology Disease Management Humans Migraine Disorders / diagnosis Practice Guidelines as Topic / standards Societies, Medical / standards

Journal

Nature reviews. Neurology
ISSN: 1759-4766
Titre abrégé: Nat Rev Neurol
Pays: England
ID NLM: 101500072

Informations de publication

Date de publication:
08 2021
Historique:
accepted: 07 05 2021
pubmed: 20 6 2021
medline: 18 1 2022
entrez: 19 6 2021
Statut: ppublish

Résumé

Migraine is a disabling primary headache disorder that directly affects more than one billion people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed and under-treated. To support clinical decision-making, we convened a European panel of experts to develop a ten-step approach to the diagnosis and management of migraine. Each step was established by expert consensus and supported by a review of current literature, and the Consensus Statement is endorsed by the European Headache Federation and the European Academy of Neurology. In this Consensus Statement, we introduce typical clinical features, diagnostic criteria and differential diagnoses of migraine. We then emphasize the value of patient centricity and patient education to ensure treatment adherence and satisfaction with care provision. Further, we outline best practices for acute and preventive treatment of migraine in various patient populations, including adults, children and adolescents, pregnant and breastfeeding women, and older people. In addition, we provide recommendations for evaluating treatment response and managing treatment failure. Lastly, we discuss the management of complications and comorbidities as well as the importance of planning long-term follow-up.

Identifiants

DOI: 10.1038/s41582-021-00509-5 PMID: 34145431 PMC: PMC8321897
pubmed: 34145431
doi: 10.1038/s41582-021-00509-5
pii: 10.1038/s41582-021-00509-5
pmc: PMC8321897
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

501-514

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021. The Author(s).

Références

Ashina, M. Migraine. N. Engl. J. Med. 383, 1866–1876 (2020).
pubmed: 33211930 doi: 10.1056/NEJMra1915327
GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 459–480 (2019).
doi: 10.1016/S1474-4422(18)30499-X
GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 954–976 (2018).
doi: 10.1016/S1474-4422(18)30322-3
[No authors listed] Headache Classification Committee of the International Headache Society (IHS) the International Classification of Headache Disorders, 3rd edition. Cephalalgia 38, 1–211 (2018).
doi: 10.1177/0333102417738202
Rasmussen, B. K. & Olesen, J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 12, 221–228 (1992).
pubmed: 1525797 doi: 10.1046/j.1468-2982.1992.1204221.x
Hansen, J. M. et al. Migraine headache is present in the aura phase. Neurology 79, 2044–2049 (2012).
pubmed: 23115208 pmcid: 3511920 doi: 10.1212/WNL.0b013e3182749eed
Natoli, J. L. et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 30, 599–609 (2010).
pubmed: 19614702 doi: 10.1111/j.1468-2982.2009.01941.x
Ashina, M. et al. Migraine and the trigeminovascular system–40 years and counting. Lancet Neurol. 18, 795–804 (2019).
pubmed: 31160203 pmcid: 7164539 doi: 10.1016/S1474-4422(19)30185-1
Ashina, M. et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 397, 1496–1504 (2021).
pubmed: 33773610 doi: 10.1016/S0140-6736(20)32162-0
Ashina, M. et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet 397, 1505–1518 (2021).
pubmed: 33773612 doi: 10.1016/S0140-6736(20)32342-4
Katsarava, Z., Mania, M., Lampl, C., Herberhold, J. & Steiner, T. J. Poor medical care for people with migraine in Europe – evidence from the Eurolight study. J. Headache Pain 19, 10 (2018).
pubmed: 29392600 pmcid: 5794675 doi: 10.1186/s10194-018-0839-1
Ashina, M. et al. Migraine: epidemiology and systems of care. Lancet 397, 1485–1495 (2021).
pubmed: 33773613 doi: 10.1016/S0140-6736(20)32160-7
Rasmussen, B. K., Jensen, R., Schroll, M. & Olesen, J. Epidemiology of headache in a general population–a prevalence study. J. Clin. Epidemiol. 44, 1147–1157 (1991).
pubmed: 1941010 doi: 10.1016/0895-4356(91)90147-2
Karsan, N. & Goadsby, P. J. Biological insights from the premonitory symptoms of migraine. Nat. Rev. Neurol. 14, 699–710 (2018).
pubmed: 30448858 doi: 10.1038/s41582-018-0098-4
Giffin, N. J., Lipton, R. B., Silberstein, S. D., Olesen, J. & Goadsby, P. J. The migraine postdrome. Neurology 87, 309–313 (2016).
pubmed: 27335112 pmcid: 4955275 doi: 10.1212/WNL.0000000000002789
Russell, M. B. & Olesen, J. A nosographic analysis of the migraine aura in a general population. Brain 119, 355–361 (1996).
pubmed: 8800932 doi: 10.1093/brain/119.2.355
Serrano, D. et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J. Headache Pain 18, 101 (2017).
pubmed: 28980171 pmcid: 5628086 doi: 10.1186/s10194-017-0787-1
Russell, M. B., Hilden, J., Sørensen, S. A. & Olesen, J. Familial occurrence of migraine without aura and migraine with aura. Neurology 43, 1369–1373 (1993).
pubmed: 8392151 doi: 10.1212/WNL.43.7.1369
Ulrich, V., Gervil, M., Kyvik, K. O., Olesen, J. & Russell, M. B. Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. Ann. Neurol. 45, 242–246 (1999).
pubmed: 9989627 doi: 10.1002/1531-8249(199902)45:2<242::AID-ANA15>3.0.CO;2-1
Russell, M. B., Fenger, K. & Olesen, J. The family history of migraine. Direct versus indirect information. Cephalalgia 16, 156–160 (1996).
pubmed: 8734766 doi: 10.1046/j.1468-2982.1996.1603156.x
Phillip, D., Lyngberg, A. & Jensen, R. Assessment of headache diagnosis. A comparative population study of a clinical interview with a diagnostic headache diary. Cephalalgia 27, 1–8 (2007).
pubmed: 17212676 doi: 10.1111/j.1468-2982.2007.01239.x
Lipton, R. B. et al. A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 61, 375–382 (2003).
pubmed: 12913201 doi: 10.1212/01.WNL.0000078940.53438.83
Láinez, M. J. A. et al. Development and validation of the migraine screen questionnaire (MS-Q). Headache 45, 1328–1338 (2005).
pubmed: 16324165 doi: 10.1111/j.1526-4610.2005.00265.x
Brighina, F. et al. A validation study of an Italian version of the ID Migraine: preliminary results. J. Headache Pain 6, 216–219 (2005).
pubmed: 16362668 pmcid: 3451999 doi: 10.1007/s10194-005-0189-7
Gil-Gouveia, R. & Martins, I. Validation of the Portuguese version of ID-Migraine. Headache 50, 396–402 (2010).
pubmed: 19473280 doi: 10.1111/j.1526-4610.2009.01449.x
Csépány, É. et al. The validation of the Hungarian version of the ID-migraine questionnaire. J. Headache Pain 19, 106 (2018).
pubmed: 30419813 pmcid: 6755580 doi: 10.1186/s10194-018-0938-z
Delic, D. et al. Translation and transcultural validation of migraine screening questionnaire (MS-Q). Med. Arch. 72, 430–433 (2018).
pubmed: 30814775 pmcid: 6340639 doi: 10.5455/medarh.2018.72.430-433
Ashina, S. et al. Tension-type headache. Nat. Rev. Dis. Primers 7, 24 (2021).
pubmed: 33767185 doi: 10.1038/s41572-021-00257-2
Fischera, M., Marziniak, M., Gralow, I. & Evers, S. The incidence and prevalence of cluster headache: a meta-analysis of population-based studies. Cephalalgia 28, 614–618 (2008).
pubmed: 18422717 doi: 10.1111/j.1468-2982.2008.01592.x
Diener, H.-C. et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 18, 891–902 (2019).
pubmed: 31174999 doi: 10.1016/S1474-4422(19)30146-2
Do, T. P. et al. Red and orange flags for secondary headaches in clinical practice. Neurology 92, 134–144 (2019).
pubmed: 30587518 pmcid: 6340385 doi: 10.1212/WNL.0000000000006697
Steiner, T. J. et al. Aids to management of headache disorders in primary care (2nd edition). J. Headache Pain 20, 57 (2019).
pubmed: 31113373 pmcid: 6734476 doi: 10.1186/s10194-018-0899-2
Mitsikostas, D. D. et al. European Headache Federation consensus on technical investigation for primary headache disorders. J. Headache Pain 17, 5 (2015).
pubmed: 26857820 doi: 10.1186/s10194-016-0596-y
Brenner, D. J. & Hall, E. J. Computed tomography–an increasing source of radiation exposure. N. Engl. J. Med. 357, 2277–2284 (2007).
pubmed: 18046031 doi: 10.1056/NEJMra072149
Evans, R. W. et al. Neuroimaging for migraine: the American Headache Society systematic review and evidence-based guideline. Headache 60, 318–336 (2019).
Sandrini, G. et al. Neurophysiological tests and neuroimaging procedures in non-acute headache (2nd edition). Eur. J. Neurol. 18, 373–381 (2011).
pubmed: 20868464 doi: 10.1111/j.1468-1331.2010.03212.x
Callaghan, B. C., Kerber, K. A., Pace, R. J., Skolarus, L. E. & Burke, J. F. Headaches and neuroimaging: high utilization and costs despite guidelines. JAMA Intern. Med. 174, 819–821 (2014).
pubmed: 24638246 pmcid: 5520970 doi: 10.1001/jamainternmed.2014.173
Evans, R. W. Incidental findings and normal anatomical variants on MRI of the brain in adults for primary headaches. Headache 57, 780–791 (2017).
pubmed: 28294311 doi: 10.1111/head.13057
Lipton, R. B. et al. Unmet acute treatment needs from the 2017 Migraine in America Symptoms and Treatment Study. Headache 59, 1310–1323 (2019).
pubmed: 31410844 pmcid: 6771753 doi: 10.1111/head.13588
Munksgaard, S. B. et al. What do the patients with medication overuse headache expect from treatment and what are the preferred sources of information? J. Headache Pain 12, 91–96 (2011).
pubmed: 21336966 pmcid: 3055992 doi: 10.1007/s10194-011-0298-4
Hepp, Z. et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35, 478–488 (2015).
pubmed: 25164920 doi: 10.1177/0333102414547138
Lipton, R. B., Pavlovic, J. M., Haut, S. R., Grosberg, B. M. & Buse, D. C. Methodological issues in studying trigger factors and premonitory features of migraine. Headache 54, 1661–1669 (2014).
pubmed: 25339181 doi: 10.1111/head.12464
Marmura, M. J. Triggers, protectors, and predictors in episodic migraine. Curr. Pain Headache Rep. 22, 81 (2018).
pubmed: 30291562 doi: 10.1007/s11916-018-0734-0
World Health Organization. Atlas of headache disorders and resources in the world 2011 (WHO, 2011).
Kirthi, V., Derry, S. & Moore, R. A. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 4, CD008041 (2013).
Rabbie, R., Derry, S. & Moore, R. A. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 4, CD008039 (2013).
Derry, S., Rabbie, R. & Moore, R. A. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2, CD008783 (2012).
Derry, S. & Moore, R. A. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 4, CD008040 (2013).
Goadsby, P. J. et al. Early vs. non-early intervention in acute migraine – ‘Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia 28, 383–391 (2008).
pubmed: 18294251 doi: 10.1111/j.1468-2982.2008.01546.x
Lantéri-Minet, M., Mick, G. & Allaf, B. Early dosing and efficacy of triptans in acute migraine treatment: the TEMPO study. Cephalalgia 32, 226–235 (2012).
pubmed: 22234883 doi: 10.1177/0333102411433042
Färkkilä, M. et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 23, 463–471 (2003).
pubmed: 12807526 doi: 10.1046/j.1468-2982.2003.00554.x
Dahlöf, C. G. H. Infrequent or non-response to oral sumatriptan does not predict response to other triptans–review of four trials. Cephalalgia 26, 98–106 (2006).
pubmed: 16426262 doi: 10.1111/j.1468-2982.2005.01010.x
Derry, C. J., Derry, S. & Moore, R. A. Sumatriptan (all routes of administration) for acute migraine attacks in adults – overview of Cochrane reviews. Cochrane Database Syst. Rev. 2014 5, CD009108 (2014).
Law, S., Derry, S. & Moore, R. A. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst. Rev. 4, CD008541 (2016).
pubmed: 27096438
[No authors listed] Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N. Engl. J. Med. 325, 316–321 (1991).
doi: 10.1056/NEJM199108013250504
Lipton, R. B. et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N. Engl. J. Med. 381, 142–149 (2019).
pubmed: 31291516 doi: 10.1056/NEJMoa1811090
Lipton, R. B. et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322, 1887–1898 (2019).
pubmed: 31742631 pmcid: 6865323 doi: 10.1001/jama.2019.16711
Goadsby, P. J. et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142, 1894–1904 (2019).
pubmed: 31132795 pmcid: 6620826 doi: 10.1093/brain/awz134
Tfelt-Hansen, P. C. & Koehler, P. J. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 28, 877–886 (2008).
pubmed: 18460007 doi: 10.1111/j.1468-2982.2008.01578.x
Bigal, M. E. & Lipton, R. B. Excessive opioid use and the development of chronic migraine. Pain 142, 179–182 (2009).
pubmed: 19232469 doi: 10.1016/j.pain.2009.01.013
Sacco, S. et al. European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J. Headache Pain 20, 6 (2019).
pubmed: 30651064 pmcid: 6734227 doi: 10.1186/s10194-018-0955-y
Bendtsen, L. et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J. Headache Pain 19, 91 (2018).
pubmed: 30259200 pmcid: 6755553 doi: 10.1186/s10194-018-0921-8
Jackson, J. L. et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS ONE 14, e0212785 (2019).
pubmed: 30893319 pmcid: 6426199 doi: 10.1371/journal.pone.0212785
Linde, M., Mulleners, W. M., Chronicle, E. P. & McCrory, D. C. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst. Rev. 6, CD010610 (2013).
Tronvik, E., Stovner, L. J., Helde, G., Sand, T. & Bovim, G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289, 65–69 (2003).
pubmed: 12503978 doi: 10.1001/jama.289.1.65
Stovner, L. J. et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 34, 523–532 (2014).
pubmed: 24335848 doi: 10.1177/0333102413515348
Stubberud, A., Flaaen, N. M., McCrory, D. C., Pedersen, S. A. & Linde, M. Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. Pain 160, 762–772 (2019).
pubmed: 30699098 doi: 10.1097/j.pain.0000000000001456
Jackson, J. L. et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ 341, C5222 (2010).
pubmed: 20961988 pmcid: 2958257 doi: 10.1136/bmj.c5222
Linde, M., Mulleners, W. M., Chronicle, E. P. & McCrory, D. C. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst. Rev. 6, CD010611 (2013).
Vatzaki, E. et al. Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. J. Headache Pain 19, 68 (2018).
pubmed: 30109437 pmcid: 6092728 doi: 10.1186/s10194-018-0898-3
Dodick, D. W. et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin. Ther. 31, 542–559 (2009).
pubmed: 19393844 doi: 10.1016/j.clinthera.2009.03.020
Couch, J. R. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 51, 33–51 (2011).
pubmed: 21070231 doi: 10.1111/j.1526-4610.2010.01800.x
Reuter, U., McClure, C., Liebler, E. & Pozo-Rosich, P. Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials. J. Neurol. Neurosurg. Psychiatry 90, 796–804 (2019).
pubmed: 30824632 doi: 10.1136/jnnp-2018-320113
Sullivan, A., Cousins, S. & Ridsdale, L. Psychological interventions for migraine: a systematic review. J. Neurol. 263, 2369–2377 (2016).
pubmed: 27159991 pmcid: 5110589 doi: 10.1007/s00415-016-8126-z
Linde, K. et al. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst. Rev. 2016, CD001218 (2016).
pmcid: 4977344
Diener, H.-C. et al. Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. Lancet 5, 310–316 (2006).
doi: 10.1016/S1474-4422(06)70382-9
Luedtke, K., Allers, A., Schulte, L. H. & May, A. Efficacy of interventions used by physiotherapists for patients with headache and migraine-systematic review and meta-analysis. Cephalalgia 36, 474–492 (2016).
pubmed: 26229071 doi: 10.1177/0333102415597889
Hindiyeh, N. A. et al. The role of diet and nutrition in migraine triggers and treatment: a systematic literature review. Headache 60, 1300–1316 (2020).
pubmed: 32449944 pmcid: 7496357 doi: 10.1111/head.13836
Bigal, M. E. & Lipton, R. B. Migraine at all ages. Curr. Pain Headache Rep. 10, 207–213 (2006).
pubmed: 18778575 doi: 10.1007/s11916-006-0047-6
Bigal, M. E., Liberman, J. N. & Lipton, R. B. Age-dependent prevalence and clinical features of migraine. Neurology 67, 246–251 (2006).
pubmed: 16864816 doi: 10.1212/01.wnl.0000225186.76323.69
Bamford, C. C., Mays, M. & Tepper, S. J. Unusual headaches in the elderly. Curr. Pain Headache Rep. 15, 295–301 (2011).
pubmed: 21455737 doi: 10.1007/s11916-011-0196-0
Vongvaivanich, K., Lertakyamanee, P., Silberstein, S. D. & Dodick, D. W. Late-life migraine accompaniments: a narrative review. Cephalalgia 35, 894–911 (2015).
pubmed: 25505036 doi: 10.1177/0333102414560635
Diener, H.-C. The risks or lack thereof of migraine treatments in vascular disease. Headache 60, 649–653 (2020).
pubmed: 31967337 doi: 10.1111/head.13749
World Health Organization. Prevention of Cardiovascular Disease: Guidelines for assessment and management of cardiovascular risk (WHO, 2007).
Barnes, N. P. Migraine headache in children. BMJ Clin. Evid. 2015, 0318 (2015).
pubmed: 26044059 pmcid: 4456852
Hershey, A. D. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol. 9, 190–204 (2010).
pubmed: 20129168 doi: 10.1016/S1474-4422(09)70303-5
Oskoui, M. et al. Practice guideline update summary: acute treatment of migraine in children and adolescents: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 93, 487–499 (2019).
pubmed: 31413171 doi: 10.1212/WNL.0000000000008095
Oskoui, M. et al. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 93, 500–509 (2019).
pubmed: 31413170 pmcid: 6746206 doi: 10.1212/WNL.0000000000008105
Evers, S., Marziniak, M., Frese, A. & Gralow, I. Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies. Cephalalgia 29, 436–444 (2009).
pubmed: 19170687 doi: 10.1111/j.1468-2982.2008.01752.x
Faber, A. J., Lagman-Bartolome, A. M. & Rajapakse, T. Drugs for the acute treatment of migraine in children and adolescents. Paediatr. Child Health 22, 454–458 (2017).
pubmed: 29479263 pmcid: 5804596 doi: 10.1093/pch/pxx170
Orr, S. L. et al. Paediatric migraine: evidence-based management and future directions. Nat. Rev. Neurol. 14, 515–527 (2018).
pubmed: 30038237 doi: 10.1038/s41582-018-0042-7
Richer, L. et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst. Rev. 4, CD005220 (2016).
pubmed: 27091010
Goadsby, P. J., Goldberg, J. & Silberstein, S. D. Migraine in pregnancy. BMJ 336, 1502–1504 (2008).
pubmed: 18583683 pmcid: 2440903 doi: 10.1136/bmj.39559.675891.AD
Amundsen, S., Nordeng, H., Nezvalová-Henriksen, K., Stovner, L. J. & Spigset, O. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat. Rev. Neurol. 11, 209–219 (2015).
pubmed: 25776823 doi: 10.1038/nrneurol.2015.29
Pasternak, B., Svanström, H., Mølgaard-Nielsen, D., Melbye, M. & Hviid, A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA 310, 1601–1611 (2013).
pubmed: 24129464 doi: 10.1001/jama.2013.278343
Vetvik, K. G. & Russell, M. B. Are menstrual and nonmenstrual migraine attacks different? Curr. Pain Headache Rep. 15, 339–342 (2011).
pubmed: 21584641 pmcid: 3165119 doi: 10.1007/s11916-011-0212-4
Vetvik, K. G., Macgregor, E. A., Lundqvist, C. & Russell, M. B. Prevalence of menstrual migraine: a population-based study. Cephalalgia 34, 280–288 (2014).
pubmed: 24101732 doi: 10.1177/0333102413507637
Newman, L. et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 41, 248–256 (2001).
pubmed: 11264684 doi: 10.1046/j.1526-4610.2001.111006248.x
Silberstein, S. & Patel, S. Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment. Expert Opin. Pharmacother. 15, 2063–2070 (2014).
pubmed: 25100506 doi: 10.1517/14656566.2014.947959
van Dijkman, S. C., de Jager, N. C. B., Rauwé, W. M., Danhof, M. & Della Pasqua, O. Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials. Clin. Pharmacokinet. 57, 1039–1053 (2018).
pubmed: 29363050 doi: 10.1007/s40262-017-0614-5
Silberstein, S. D. et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology 78, 1337–1345 (2012).
pubmed: 22529202 pmcid: 3335452 doi: 10.1212/WNL.0b013e3182535d20
Lipton, R. B. et al. Validity and reliability of the migraine-treatment optimization questionnaire. Cephalalgia 29, 751–759 (2009).
pubmed: 19239676 doi: 10.1111/j.1468-2982.2008.01786.x
Steiner, T. J. et al. The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: development, psychometric evaluation and assessment of utility. J. Headache Pain 19, 15 (2018).
pubmed: 29445880 pmcid: 5812954 doi: 10.1186/s10194-018-0842-6
Steiner, T. J. et al. Recommendations for headache service organisation and delivery in Europe. J. Headache Pain 12, 419–426 (2011).
pubmed: 21380555 pmcid: 3139057 doi: 10.1007/s10194-011-0320-x
World Health Organization. Building the economic case for primary health care: a scoping review. Technical series on primary health care (WHO, 2018).
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1211–1259 (2017).
doi: 10.1016/S0140-6736(17)32154-2
Diener, H. C. et al. European Academy of Neurology guideline on the management of medication-overuse headache. Eur. J. Neurol. 27, 1102–1116 (2020).
pubmed: 32430926 doi: 10.1111/ene.14268
Kristoffersen, E. S. et al. Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial. J. Neurol. Neurosurg. Psychiatry 86, 505–512 (2015).
pubmed: 25112307 doi: 10.1136/jnnp-2014-308548
Kristoffersen, E. S. et al. Brief intervention by general practitioners for medication-overuse headache, follow-up after 6 months: a pragmatic cluster-randomised controlled trial. J. Neurol. 263, 344–353 (2016).
pubmed: 26645391 doi: 10.1007/s00415-015-7975-1
Lai, J. T. F. et al. Should we educate about the risks of medication overuse headache? J. Headache Pain 15, 10 (2014).
pubmed: 24524380 pmcid: 3942071 doi: 10.1186/1129-2377-15-10
Pijpers, J. A. et al. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain 142, 1203–1214 (2019).
pubmed: 30982843 pmcid: 6511115 doi: 10.1093/brain/awz052
Carlsen, L. N. et al. Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol. 77, 1069–1078 (2020).
pubmed: 32453406 doi: 10.1001/jamaneurol.2020.1179
Buse, D. C. et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52, 1456–1470 (2012).
pubmed: 22830411 doi: 10.1111/j.1526-4610.2012.02223.x
Diener, H.-C. et al. Chronic migraine — classification, characteristics and treatment. Nat. Rev. Neurol. 8, 162–171 (2012).
pubmed: 22331030 doi: 10.1038/nrneurol.2012.13
Buse, D. C., Greisman, J. D., Baigi, K. & Lipton, R. B. Migraine progression: a systematic review. Headache 59, 306–338 (2019).
pubmed: 30589090 doi: 10.1111/head.13459
Probyn, K. et al. Prognostic factors for chronic headache: a systematic review. Neurology 89, 291–301 (2017).
pubmed: 28615422 pmcid: 5513814 doi: 10.1212/WNL.0000000000004112
Xu, J., Kong, F. & Buse, D. C. Predictors of episodic migraine transformation to chronic migraine: a systematic review and meta-analysis of observational cohort studies. Cephalalgia 40, 503–516 (2019).
pubmed: 31635478 doi: 10.1177/0333102419883355
Lipton, R. B. et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84, 688–695 (2015).
pubmed: 25609757 pmcid: 4336107 doi: 10.1212/WNL.0000000000001256
Silberstein, S. et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49, 1153–1162 (2009).
pubmed: 19719543 doi: 10.1111/j.1526-4610.2009.01508.x
Herd, C. P. et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst. Rev. 6, CD011616 (2018).
pubmed: 29939406
Charles, A. & Pozo-Rosich, P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 394, 1765–1774 (2019).
pubmed: 31668411 doi: 10.1016/S0140-6736(19)32504-8
Reuter, U. et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392, 2280–2287 (2018).
pubmed: 30360965 doi: 10.1016/S0140-6736(18)32534-0
Ferrari, M. D. et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394, 1030–1040 (2019).
pubmed: 31427046 doi: 10.1016/S0140-6736(19)31946-4
Ruff, D. D. et al. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. Eur. J. Neurol. 27, 609–618 (2020).
pubmed: 31692188 doi: 10.1111/ene.14114
Dresler, T. et al. Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J. Headache Pain 20, 51 (2019).
pubmed: 31072313 pmcid: 6734261 doi: 10.1186/s10194-019-0988-x
Lampl, C. et al. Headache, depression and anxiety: associations in the Eurolight project. J. Headache Pain 17, 59 (2016).
pubmed: 27245683 pmcid: 4887397 doi: 10.1186/s10194-016-0649-2
Buse, D. C. et al. Sleep disorders among people with migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 59, 32–45 (2019).
pubmed: 30381821 doi: 10.1111/head.13435
Ashina, S. et al. Increased pain sensitivity in migraine and tension-type headache coexistent with low back pain: A cross-sectional population study. Eur. J. Pain 22, 904–914 (2018).
pubmed: 29349847 doi: 10.1002/ejp.1176
Ashina, S. et al. Prevalence of neck pain in migraine and tension-type headache: a population study. Cephalalgia 35, 211–219 (2015).
pubmed: 24853166 doi: 10.1177/0333102414535110
Buse, D. C., Manack, A., Serrano, D., Turkel, C. & Lipton, R. B. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J. Neurol. Neurosurg. Psychiatry 81, 428–432 (2010).
pubmed: 20164501 doi: 10.1136/jnnp.2009.192492
Bigal, M. E. & Lipton, R. B. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 67, 252–257 (2006).
pubmed: 16864817 doi: 10.1212/01.wnl.0000225052.35019.f9
Kurth, T., Schürks, M., Logroscino, G. & Buring, J. E. Migraine frequency and risk of cardiovascular disease in women. Neurology 73, 581–588 (2009).
pubmed: 19553594 pmcid: 2731618 doi: 10.1212/WNL.0b013e3181ab2c20
Westergaard, M. L. S. et al. The headache under-response to treatment (HURT) questionnaire: assessment of utility in headache specialist care. Cephalalgia 33, 245–255 (2013).
pubmed: 23236098 doi: 10.1177/0333102412469740
Al Jumah, M. et al. HURT (Headache Under-Response to Treatment) questionnaire in the management of primary headache disorders: reliability, validity and clinical utility of the Arabic version. J. Headache Pain 14, 16 (2013).
pubmed: 23565801 pmcid: 3620405 doi: 10.1186/1129-2377-14-16
Lipton, R., Manack, A., Serrano, D. & Buse, D. Acute treatment optimization for migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. J. Headache Pain 14, P201 (2013).
pmcid: 3620241 doi: 10.1186/1129-2377-14-S1-P201

Auteurs

Anna K Eigenbrodt (AK)

Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID: 0000-0001-5031-8971

Håkan Ashina (H)

Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Sabrina Khan (S)

Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID: 0000-0002-0953-5701

Hans-Christoph Diener (HC)

Institute for Medical Informatics, Biometry and Epidemiology, Medical Faculty, University Duisburg-Essen, Essen, Germany.
ORCID: 0000-0002-6556-8612

Dimos D Mitsikostas (DD)

First Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Alexandra J Sinclair (AJ)

Metabolic Neurology, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Birmingham Neuro-Ophthalmology, Queen Elizabeth Hospital, Birmingham, UK.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK.
Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, UK.
ORCID: 0000-0003-2777-5132

Patricia Pozo-Rosich (P)

Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
ORCID: 0000-0003-0796-4702

Paolo Martelletti (P)

Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Regional Referral Headache Centre, Sant'Andrea Hospital, Rome, Italy.
ORCID: 0000-0002-6556-4128

Anne Ducros (A)

Neurology Department, Montpellier University Hospital, Montpellier, France.
ORCID: 0000-0001-5560-5013

Michel Lantéri-Minet (M)

Departement d'Evaluation et Traitement de la Douleur, Centre Hospitalo-Universitaire de Nice, Nice, France.

Mark Braschinsky (M)

Neurology Clinic, Tartu University Hospital, Tartu, Estonia.
ORCID: 0000-0002-3457-0242

Margarita Sanchez Del Rio (MS)

Department of Neurology, Clínica Universidad de Navarra, Madrid, Spain.

Oved Daniel (O)

Headache & Facial Pain Clinic, Laniado Medical Center, Netanya, Israel.
ORCID: 0000-0002-8232-9138

Aynur Özge (A)

Department of Neurology, Mersin University Medical Faculty, Mersin, Turkey.
ORCID: 0000-0003-2797-2398

Ayten Mammadbayli (A)

Department of Neurology, Azerbaijan State Medical University, Baku, Azerbaijan.

Mihails Arons (M)

Department of Anesthesiology and Intensive Care, P. Stradins University, Riga, Latvia.
ORCID: 0000-0002-3888-2630

Kirill Skorobogatykh (K)

University Headache Clinic, Moscow, Russia.
ORCID: 0000-0002-1279-9548

Vladimir Romanenko (V)

Ukrainian Institute of Family Medicine, Kiev, Ukraine.

Gisela M Terwindt (GM)

Department of Neurology, Leiden University Medical Center, Leiden, Netherlands.

Koen Paemeleire (K)

Department of Neurology, Ghent University Hospital, Ghent, Belgium.
ORCID: 0000-0001-8103-3899

Simona Sacco (S)

Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy.
ORCID: 0000-0003-0651-1939

Uwe Reuter (U)

Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.
ORCID: 0000-0002-8527-0725

Christian Lampl (C)

Headache Medical Center, Seilerstaette Linz, Linz, Austria.
Department of Geriatric Medicine, Ordensklinikum Linz, Linz, Austria.

Henrik W Schytz (HW)

Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
ORCID: 0000-0002-6262-2986

Zaza Katsarava (Z)

Department of Neurology, University of Duisburg-Essen, Essen, Germany.
Department of Neurology, Evangelical Hospital Unna, Unna, Germany.
EVEX Medical Corporation, Tbilisi, Georgia.
Department of Nervous Diseases of the Institute of Professional Education, IM Sechenov First Moscow State Medical University, Moscow, Russia.
ORCID: 0000-0002-9932-1159

Timothy J Steiner (TJ)

Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, NTNU Norwegian University of Science and Technology, Trondheim, Norway.
Division of Brain Sciences, Imperial College London, London, UK.
ORCID: 0000-0002-1882-4337

Messoud Ashina (M)

Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ashina@dadlnet.dk.
Department of Nervous Diseases of the Institute of Professional Education, IM Sechenov First Moscow State Medical University, Moscow, Russia. ashina@dadlnet.dk.
Danish Knowledge Center on Headache Disorders, Glostrup, Denmark. ashina@dadlnet.dk.
Department of Neurology, Azerbaijan Medical University, Baku, Azerbaijan. ashina@dadlnet.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Diagnostic › Prise de décision clinique › Diagnosis and management of migraine in ten steps.
Recherchemedicale.com › Phénomènes psychologiques › Processus mentaux › Pensée (activité mentale) › Prise de décision › Consensus › Diagnosis and management of migraine in ten steps.
Recherchemedicale.com › Régions géographiques › Europe › Pays nordiques et scandinaves › Danemark › Diagnosis and management of migraine in ten steps.
Recherchemedicale.com › Administration des services de santé › Gestion des soins aux patients › Prise en charge de la maladie › Diagnosis and management of migraine in ten steps.
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Diagnosis and management of migraine in ten steps.
Recherchemedicale.com › Maladies du système nerveux › Maladies du système nerveux central › Encéphalopathies › Céphalées › Céphalées primitives › Migraines › Diagnosis and management of migraine in ten steps.
Recherchemedicale.com › Qualité, accès, évaluation des soins de santé › Assurance de la qualité des soins de santé › Recommandations comme sujet › Guides de bonnes pratiques cliniques comme sujet › Diagnosis and management of migraine in ten steps.
Recherchemedicale.com › Organisations et économie des soins de santé › Organismes › Sociétés › Sociétés médicales › Diagnosis and management of migraine in ten steps.